These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20462510)

  • 1. Gender disparity in cardiac electrophysiology: implications for cardiac safety pharmacology.
    Jonsson MK; Vos MA; Duker G; Demolombe S; van Veen TA
    Pharmacol Ther; 2010 Jul; 127(1):9-18. PubMed ID: 20462510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
    Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
    Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs for men and women - how important is gender as a risk factor for TdP?
    Coker SJ
    Pharmacol Ther; 2008 Aug; 119(2):186-94. PubMed ID: 18472167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidences of the gender-related differences in cardiac repolarization and the underlying mechanisms in different animal species and human.
    Cheng J
    Fundam Clin Pharmacol; 2006 Feb; 20(1):1-8. PubMed ID: 16448390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
    Milberg P; Hilker E; Ramtin S; Cakir Y; Stypmann J; Engelen MA; Mönnig G; Osada N; Breithardt G; Haverkamp W; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):647-54. PubMed ID: 17388913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
    Milberg P; Eckardt L; Bruns HJ; Biertz J; Ramtin S; Reinsch N; Fleischer D; Kirchhof P; Fabritz L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Oct; 303(1):218-25. PubMed ID: 12235254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in understanding sex differences in cardiac repolarization.
    James AF; Choisy SC; Hancox JC
    Prog Biophys Mol Biol; 2007 Jul; 94(3):265-319. PubMed ID: 15979693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical assessment of drug-induced proarrhythmias: role of the arterially perfused rabbit left ventricular wedge preparation.
    Wang D; Patel C; Cui C; Yan GX
    Pharmacol Ther; 2008 Aug; 119(2):141-51. PubMed ID: 18423604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced long QT syndrome and torsade de pointes.
    Morissette P; Hreiche R; Turgeon J
    Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
    Calderone V; Cavero I
    Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The continuing evolution of torsades de pointes liability testing methods: is there an end in sight?
    Lee N; Authier S; Pugsley MK; Curtis MJ
    Toxicol Appl Pharmacol; 2010 Mar; 243(2):146-53. PubMed ID: 20005885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case series of drug-induced long QT syndrome and Torsade de Pointes.
    Tong KL; Lau YS; Teo WS
    Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes.
    Antzelevitch C; Sun ZQ; Zhang ZQ; Yan GX
    J Am Coll Cardiol; 1996 Dec; 28(7):1836-48. PubMed ID: 8962574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation.
    Di Diego JM; Belardinelli L; Antzelevitch C
    Circulation; 2003 Aug; 108(8):1027-33. PubMed ID: 12912819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
    Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
    Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs.
    Thomsen MB; Verduyn SC; Stengl M; Beekman JD; de Pater G; van Opstal J; Volders PG; Vos MA
    Circulation; 2004 Oct; 110(16):2453-9. PubMed ID: 15477402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex hormonal regulation of cardiac ion channels in drug-induced QT syndromes.
    Kurokawa J; Kodama M; Clancy CE; Furukawa T
    Pharmacol Ther; 2016 Dec; 168():23-28. PubMed ID: 27595633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimalarial drugs: QT prolongation and cardiac arrhythmias.
    Traebert M; Dumotier B
    Expert Opin Drug Saf; 2005 May; 4(3):421-31. PubMed ID: 15934850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo mechanisms precipitating torsades de pointes in a canine model of drug-induced long-QT1 syndrome.
    Gallacher DJ; Van de Water A; van der Linde H; Hermans AN; Lu HR; Towart R; Volders PG
    Cardiovasc Res; 2007 Nov; 76(2):247-56. PubMed ID: 17669388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database.
    Aström-Lilja C; Odeberg JM; Ekman E; Hägg S
    Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):587-92. PubMed ID: 18449951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.